Relapsing Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis [Phase 3]
Phase 3 single-arm trial evaluating the efficacy, safety and tolerability of ofatumumab in Relapsing Multiple Sclerosis has completed with r…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab [Phase 4]
Phase 4 multicenter study results evaluating immune response to influenza vaccination in adults with relapsing multiple sclerosis treated wi…
-
CLINICAL_TRIALS trial_result · 2024-06-20Clinical Trial Update: A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab [Phase 4]
This Phase 4 open-label study evaluated the immune response to COVID-19 vaccination in people with relapsing multiple sclerosis treated with…
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) [Phase 2]
Phase 2 clinical trial evaluating the efficacy of Fenebrutinib in Relapsing Multiple Sclerosis. Results were posted in 2024.
-
FDA approval · 2024-06-05FDA Approved: TASCENSO ODT — Supplemental Application (Cycle Pharmaceuticals Ltd)
FDA approved a supplemental application for Tasenso ODT (fingolimod lauryl sulfate), introducing a new orodispersible tablet formulation of …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) [Phase 3]
Phase 3 study exploring the mechanism of action of ocrelizumab and B-cell biology in relapsing and primary progressive multiple sclerosis; r…
-
CLINICAL_TRIALS trial_result · 2024-06-03Clinical Trial Update: Natalizumab Subcutaneous Immunogenicity and Safety Study [Phase 2]
Phase 2 study evaluating subcutaneous natalizumab for immunogenicity and safety has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
This clinical trial update reports the completion of a study evaluating the effectiveness and safety of Mayzent (fingolimod) in Chinese pati…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Effects of Cladribine Tablets on the PK of Microgynon® [Phase 1]
Phase 1 trial evaluating effects of cladribine tablets on the pharmacokinetics of Microgynon® in relapsing multiple sclerosis patients has c…
-
CLINICAL_TRIALS trial_result · 2023-12-08Clinical Trial Update: A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis [Phase 2, Phase 3]
A long-term open-label extension study of CNM-Au8 in relapsing multiple sclerosis has completed phases 2 and 3.
-
FDA label_change · 2023-08-10FDA Approved: ZEPOSIA 7-DAY STARTER PACK — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental submission to add a 7-day starter pack for Zeposia (ozanimod hydrochloride) to initiate therapy. This update…
-
FDA approval · 2023-08-10FDA Approved: PONVORY — Supplemental Application (Janssen Pharmaceuticals, Inc)
The FDA approved a supplemental application for PONVORY (ponesimod) from Janssen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients [Phase 3]
Phase 3 trial assessing safety and tolerability of converting relapsing multiple sclerosis patients from oral, injectable, or infusion disea…
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis [Phase 4]
Phase 4 trial updating safety and efficacy of teriflunomide in relapsing forms of multiple sclerosis after completion.
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis [Phase 2]
This update summarizes a Phase 2 dose-finding trial of SAR442168 for relapsing multiple sclerosis, with results posted after study completio…
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab [Phase 2]
Phase 2 trial evaluating efficacy and safety of ofatumumab versus placebo in relapsing multiple sclerosis with open-label extension.
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) [Phase 3]
Phase 3 clinical trial evaluating efficacy and safety of ublituximab in relapsing multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) [Phase 3]
A Phase 3 trial assessing the efficacy and safety of ublituximab in relapsing forms of multiple sclerosis (ULTIMATE 1) has completed with re…
-
CLINICAL_TRIALS trial_result · 2021-02-11Clinical Trial Update: Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis [Phase 3]
Phase 3 trial update on OZanimod for relapsing multiple sclerosis reports efficacy and safety findings.
-
CLINICAL_TRIALS trial_result · 2021-02-11Clinical Trial Update: Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients [Phase 2, Phase 3]
Clinical trial update on Ozanimod (RPC1063) in relapsing multiple sclerosis reports results from Phase 2 and Phase 3 efficacy and safety ana…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. [Phase 3]
Phase 3 trial comparing ofatumumab to teriflunomide in relapsing multiple sclerosis; results completed with posted data.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis [Phase 3]
Phase 3 trial comparing ofatumumab to teriflunomide in relapsing multiple sclerosis completed with results posted.
-
FDA approval · 2020-08-20FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Kesimpta (ofatumumab) from Novartis Pharmaceuticals Corporation, expanding its label/indicat…
-
CLINICAL_TRIALS trial_result · 2020-07-21Clinical Trial Update: A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod [Phase 4]
Phase 4 clinical trial evaluating immune phenotype biomarkers in relapsing multiple sclerosis patients treated with fingolimod 0.5 mg; compl…
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients [Phase 2]
Phase 2 trial update on fecal microbiota transplantation in relapsing multiple sclerosis has been terminated with results posted.